The association of SOD and HsCRP with the efficacy of sulforaphane in schizophrenia patients with residual negative symptoms
-
Published:2023-09-20
Issue:
Volume:
Page:
-
ISSN:0940-1334
-
Container-title:European Archives of Psychiatry and Clinical Neuroscience
-
language:en
-
Short-container-title:Eur Arch Psychiatry Clin Neurosci
Author:
Zeng Jianfei, Zhang Weizhi, Lu Xiaobing, Zhou Hui, Huang Jing, Xu Zhenyu, Liao Hairong, Liang Jiaquan, Liang Meihong, Ye Chan, Sun Ting, Hu Yutong, She Qi, Chen Haixia, Guo Qian, Yan LiuJiao, Wu Renrong, Li ZezhiORCID
Abstract
Abstract
Objectives
Emerging evidence indicates a connection between oxidative stress, immune-inflammatory processes, and the negative symptoms of schizophrenia. In addition to possessing potent antioxidant and anti-inflammatory properties, sulforaphane (SFN) has shown promise in enhancing cognitive function among individuals with schizophrenia. This study aims to investigate the efficacy of combined treatment with SFN in patients with schizophrenia who experience negative symptoms and its effect on the levels of superoxide dismutase (SOD) and the inflammatory marker, high-sensitivity C-reactive protein (HsCRP).
Design
Forty-five patients with schizophrenia were recruited, who mainly experienced negative symptoms during a stable period. In addition to the original treatments, the patients received SFN tablets at a daily dose of 90 mg for 24 weeks. At baseline, 12 weeks, and 24 weeks, the participants were interviewed and evaluated. The reduction rate of the Positive and Negative Syndrome Scale (PANSS) was used to assess each participant. The side effects scale of Treatment Emergent Symptom Scale (TESS) was applied to assess the adverse reactions. Additionally, the levels of the SOD, HsCRP, and other indicators were examined.
Results
The study findings revealed a significant decrease in PANSS negative subscale scores (P < 0.001). Furthermore, there was a significant increase in SOD activity and HsCRP levels (P < 0.001 and P < 0.05). Notably, the group of participants who exhibited a reduction in PANSS negative subscale scores demonstrated a significant improvement in HsCRP levels (P < 0.05).
Conclusions
Our study suggests that SFN may potentially serve as a safe adjunctive intervention to improve the negative symptoms of schizophrenia. The potential mechanism by which SFN improves negative symptoms in schizophrenia patients may involve its anti-inflammatory properties, specifically its ability to reduce HsCRP levels.
Trial registration
ClinicalTrial.gov (ID: NCT03451734).
Funder
Guangzhou municipal key discipline in medicine Open Project Program of State Key Laboratory of Virtual Reality Technology and Systems, Beihang University Shanghai Key Laboratory of Psychotic Disorders Open Grant Guangzhou Key R&D Program Agriculture and Social Development Science and Technology Project Tianjin Science and Technology Project Opening Foundation of Jiangsu Key Laboratory of Neurodegeneration, Nanjing Medical University Guangzhou Municiple Health Commission Tertiary Education Scientific research project of Guangzhou Municipal Education Bureau
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Biological Psychiatry,Psychiatry and Mental health,General Medicine
Reference43 articles.
1. Coyle JT (2017) Schizophrenia: Basic and clinical. Adv Neurobiol 15:255–280 2. Zhu MH, Liu ZJ, Hu QY, Yang JY, Jin Y, Zhu N, Huang Y, Shi DH, Liu MJ, Tan HY, Zhao L, Lv QY, Yi ZH, Wu FC, Li ZZ (2022) Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial. Mil Med Res 9:59 3. Lee SJ, Kim KR, Lee SY, An SK (2017) Impaired social and role function in ultra-high risk for psychosis and first-episode schizophrenia: Its relations with negative symptoms. Psychiatry Investig 14:539–545 4. Kaneko K (2018) Negative symptoms and cognitive impairments in schizophrenia: Two key symptoms negatively influencing social functioning. Yonago Acta Med 61:91–102 5. Pandurangi AK, Buckley PF (2020) Inflammation, antipsychotic drugs, and evidence for effectiveness of anti-inflammatory agents in schizophrenia. Curr Top Behav Neurosci 44:227–244
|
|